Firmagon (Degarelix) Indication
Firmagon (degarelix) is indicated for the treatment of patients with advanced prostate cancer requiring androgen deprivation therapy. 1
FDA-Approved Indication
Firmagon is a gonadotropin-releasing hormone (GnRH) receptor antagonist specifically approved for treatment of patients with advanced prostate cancer 1. This represents the official FDA indication established in 2008.
Clinical Context and Use
Role in Advanced Prostate Cancer Management
Firmagon serves as one of several androgen deprivation therapy (ADT) options for men with advanced prostate cancer. According to current ASCO guidelines, when ADT is indicated for metastatic noncastrate prostate cancer, it should be combined with additional agents (docetaxel, abiraterone, enzalutamide, or apalutamide) rather than used as monotherapy 2.
Mechanism and Clinical Advantages
Degarelix works through direct GnRH receptor blockade, producing immediate testosterone suppression without the initial testosterone surge seen with GnRH agonists 3, 4. This eliminates the risk of clinical flare in patients with advanced disease—a significant advantage over traditional GnRH agonists like leuprolide.
Key clinical benefits include:
- Faster testosterone suppression compared to GnRH agonists
- No testosterone surge or microsurges
- More rapid PSA decline
- No requirement for anti-androgen co-administration to prevent flare
Dosing Regimen
The FDA-approved dosing is:
- Starting dose: 240 mg (given as two 120 mg subcutaneous injections)
- Maintenance dose: 80 mg subcutaneous injection every 28 days 1
A 3-month formulation (480 mg maintenance dose every 84 days) has been studied and shown non-inferiority in testosterone suppression 5.
Important Safety Considerations
Common Adverse Events
The most frequent adverse reaction is injection site reactions (pain, erythema, swelling) occurring in approximately 40% of patients 1. Other common effects include:
- Hot flashes (≥10%)
- Elevated liver transaminases and GGT (≥10%)
- QT interval prolongation risk 1
Critical Warnings
- Hypersensitivity reactions including anaphylaxis have been reported—discontinue if severe reaction occurs 1
- Embryo-fetal toxicity: Can cause fetal harm and pregnancy loss 1
- Cardiovascular effects: While one small study suggested reduced cardiovascular events, this evidence is very uncertain and was in a high-risk population 3
Comparative Effectiveness
Degarelix demonstrates similar overall efficacy to GnRH agonists in achieving testosterone suppression, with no difference in serious adverse events or quality of life 3. However, the evidence base is limited by short follow-up (maximum 14 months in most studies) and lack of data on overall survival or cancer-specific survival 3.
The primary trade-off is increased injection site pain (RR 15.68) compared to GnRH agonists, balanced against faster testosterone suppression and elimination of flare risk 3.
Clinical Positioning
In contemporary practice, Firmagon represents a first-line ADT option particularly suitable for:
- Patients with symptomatic metastatic disease where rapid testosterone suppression is desired
- Patients at risk for clinical flare complications
- Patients requiring immediate castration without anti-androgen coverage
However, ADT alone (whether degarelix or GnRH agonist) is no longer the standard of care for metastatic noncastrate prostate cancer—combination therapy with novel hormonal agents or chemotherapy is now recommended 2, 6.